ArticleNucleic acids research2026
Coupling DNA intercalation with redox catalysis: selective killing mechanism of glioblastoma by daidzin.
Article in Nucleic acids research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Isoflavones as multi-target modulators in glioma and neuroblastoma: a mini-review.Pharmacological reports : PR · 2026Review
- DNER drives glycolytic reprogramming in renal cell carcinoma by activating the JAK2/STAT3 signaling pathway.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Glioblastoma (GBM) is recognized as one of the most treatment-resistant malignancies, owing to its reinforced DNA repair systems and limited drug accessibility across the blood-brain barrier. This study, identifies, daidzin (DZN), a naturally derived isoflavone, as a potent redox-active DNA intercalator that intrinsically combines physical intercalation with chemical reactivity to breach this resistance. Unlike traditional intercalators, DZN autonomously triggers destabilization of DNA helices by inducing torsional strain, thereby producing convergent strand and base lesions through photo-independent redox pathways involving deoxyribose cleavage and C8 guanine oxidation. Additionally, DZN demonstrates pronounced glioma-specific cytotoxicity by initiating 1O2-driven oxo-cation formation and concomitant H2O2 production. This redox burst results in DNA strand scission activating robust DDR signaling and oxidative base lesions, which cripple tumor survival. Enhanced membrane fluidity in glioma cells likely facilitates superior DZN permeability, intracellular accumulation, thereby allowing DZN to initiate this robust DNA damage responses, culminating in G1 arrest and apoptosis in GBM cells while sparing normal glia. In vivo, DZN markedly suppresses tumor growth and surpasses temozolomide efficacy, current clinical option for GBM treatment. This work, thus, establishes a previously unrecognized paradigm of DNA intercalation-driven redox chemistry, presenting DZN as a promising therapeutic capable of exploiting the genomic frailties to overcome therapeutic resistance in glioma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.